The Numbers Are In — and They're Big

Novo Nordisk's Wegovy pill crossed 2 million total prescriptions in its first quarter on the U.S. market, according to CNBC. Sales beat expectations even at a lower price point than the injection.

When the pill went live in January, telehealth provider LifeMD saw patient intake jump from 300–400 new patients per day to 600–1,000, according to LifeMD CEO Justin Schreiber. He told CNBC he expected demand, but not at that scale.

Who's Actually Taking This Pill

The Wegovy pill isn't stealing patients from Wegovy injections. It's pulling in an entirely new category of patients.

CNBC spoke with five U.S. patients who recently started the pill. Every single one said they had never previously taken a branded GLP-1 injection. The barriers were familiar — needle fear, high out-of-pocket injection costs, general skepticism about committing to a shot.

Jane Zuckerman, a 32-year-old data analyst in Washington, D.C., is one example. She lost 90 pounds in college, fought her weight back for years through nutritionists, therapy, and strict routines, hit 270 pounds post-pandemic, and refused GLP-1 injections because she's afraid of needles. She called her doctor the day the pill became available. After roughly a month on it, she reported losing around 11 pounds, according to CNBC.

Novo isn't cannibalizing its own injection revenue. It's growing the total market.

Lilly's Pill Arrived Three Months Late and Quietly

Eli Lilly just won U.S. approval for its own GLP-1 obesity pill, Foundayo. But it launched roughly three months after Wegovy's pill, and early signals are not flattering.

BMO Capital Markets analyst Evan David Seigerman told CNBC that Wall Street had expected Lilly to dominate the oral category the way it came to dominate injectables. Lilly itself had been telling investors its pill was easier to manufacture and wouldn't face the shortages that hampered Wegovy shots.

That narrative is now cracking.

Novo's oral semaglutide delivered nearly 17% average body weight loss in clinical trials. Lilly's pill came in at roughly 12% in its comparable data, per CNBC's reporting. Novo spotted that gap last summer and started hammering the efficacy difference publicly. It worked.

The Global Push

Novo is now moving to take the pill global.

Emil Kongshøj Larsen, Novo Nordisk's Executive Vice President for International Operations, told CNBC directly: "When we launch, we'll go all in. It's a major opportunity."

Novo announced last week it expects to begin first launches outside the U.S. later this year, pending regulatory approvals. Larsen wouldn't name specific countries but pointed to patient demand, physician training levels, and telehealth infrastructure as the key variables for sequencing rollouts. He specifically called out Germany, where telehealth has recently unlocked access that traditional healthcare channels couldn't deliver.

Analysts cited by CNBC highlight the UK, Germany, and Denmark as the most likely first international launch markets.

Right now, the U.S. accounts for more than half of both Novo's and Eli Lilly's total sales. If oral GLP-1s crack international markets the way they've cracked the U.S., the revenue math changes dramatically.

Novo Is Still Losing Money in 2026

Despite all of this momentum, Novo still expects its profits and sales to decline between 4% and 12% in 2026, according to company guidance reported by ad-hoc-news.de and CNBC. The culprits: lower drug prices in the U.S. and generic competition eating into revenue in India, Canada, Brazil, and China.

Novo bumped its guidance slightly upward last week — but it's still guiding down. Meanwhile, Eli Lilly is projecting 28% sales growth at the midpoint of its 2026 guidance.

Novo is winning the pill race on prescriptions and patient expansion, and it's still seeing revenue decline overall. Novo is winning on prescriptions and patient expansion, but its guidance suggests the pill's lower price point is real, the generic erosion in emerging markets is real, and the road to profitability on oral GLP-1s globally is longer than the headline numbers suggest.

What This Means for Regular People

If you've been sitting on the sidelines because you hate needles or couldn't afford injection costs, the pill market just got more competitive — which means prices will eventually move. Foundayo's entry gives patients a second option. More options mean more negotiating leverage, eventually.

The global launch push also matters: international regulatory approvals and reimbursement fights will determine whether this becomes a global public health shift or stays an expensive American trend.

Novo has the early lead. Whether it can hold it — against Lilly, against generics, and against its own cost structure — remains an open question.